Xcovery and Betta Pharmaceuticals' ALK Inhibitor, Ensartinib, Receives FDA Approval Based on Successful Phase 1/2 Trial Results
Study Background and Drug Profile
Xcovery Holdings, Inc. and Betta Pharmaceuticals (300558.SZ) co-developed Ensartinib (brand name: Ensacove), an oral, second-generation targeted therapy for ALK-positive non-small cell lung cancer (NSCLC). This drug selectively inhibits multiple cancer-causing molecules, including ALK, c-MET, and ROS1, in addition to its primary target, ALK, in an attempt to overcome resistance to existing treatments. The initial Phase 1/2 clinical trial (NCT01625234) was designed to determine the optimal recommended dose and demonstrate safety, paving the way for subsequent clinical trials. A key feature is its molecular structure, which maximizes central nervous system (CNS) penetration to improve the control of brain metastases in ALK-mutated patients, as this is a critical factor in treatment success.
Clinical Results and Safety Profile
In the Phase 1/2 clinical trial, Ensartinib achieved an objective response rate (ORR) of 60% and a median progression-free survival (mPFS) of 9.2 months at the recommended Phase 2 dose of 225mg. In particular, the first-line treatment group (TKI-naïve) showed an ORR of 80% and an impressive mPFS of 26.2 months, demonstrating excellent efficacy. Furthermore, the CNS ORR was 64%, indicating strong clinical utility for patients with brain metastases. Adverse events were mainly mild and manageable, such as skin rash (56%) and nausea (36%), demonstrating a favorable safety profile suitable for long-term use.
Market Outlook and Competitive Landscape
The global ALK-positive NSCLC market is a key precision medicine area with high growth potential, estimated at approximately USD 5.24 billion in 2026 and USD 9.8 billion in 2033. Currently, Roche's Alectinib (brand name: Alecensa) dominates this market, with annual sales of USD 1.65 billion in 2023. Pfizer's Lorlatinib (brand name: Lorbrena) is also rapidly increasing its market share as a third-generation treatment, achieving sales of USD 1.65 billion in 2024. In this competitive landscape, where Alectinib and Lorlatinib share the market, Takeda's Brigatinib (brand name: Alunbrig) is also aggressively pursuing market share.
Regulatory History and Commercialization Strategy
Based on the results of the completed Phase 3 trial (eXalt3, NCT02767804) and the initial clinical results, Ensartinib received official FDA approval on December 18, 2024. The fact that the FDA review process did not require a separate advisory committee (AdComm) meeting is a significant indicator that the drug's excellent safety and efficacy have been recognized. In April 2026, a strategic commercialization cooperation agreement was signed with Eversana, a global healthcare services company, to ensure successful distribution and market access in the United States. This marks a significant step towards full commercialization and the realization of global sales.
The favorable data from the Phase 1/2 trial (NCT01625234), including CNS ORR of 64% and mPFS of 26.2 months in the first-line treatment (TKI-naïve) patient population, served as a critical foundation for Ensartinib's FDA approval and successful market entry. In the global ALK-positive NSCLC market, valued at USD 5.24 billion, where Roche's Alectinib (USD 1.65 billion) and Pfizer's Lorlatinib (USD 1.65 billion) hold a leading position, Ensartinib, as a second-generation new drug, has the potential to reshape market share by offering a unique treatment option. In the short term, the commercialization performance through the distribution agreement with Eversana will be a key indicator, and in the medium to long term, expanding the multi-target treatment strategy for c-MET and ROS1 in patients with resistance to existing competitive products will be crucial for enhancing pipeline value. Betta Pharmaceuticals' USD 20 million equity investment, securing Asian market rights, and the synergy of the global distribution strategy are expected to drive stable sales growth, despite being a late entrant.
Source: ClinicalTrials.gov (api_ct)